Trial Information

Summary: A Multicenter, Randomized, Double-Blind, Comparison Study Of The Safety And Efficacy Of A Once-Daily Dose Of Tigecycline Versus Ertapenem For The Treatment Of Foot Infections In Subjects With Diabetes

Diagnosis:
Men and women aged 18 or older with diabetes and a qualifying foot infection

Qualifying subjects will be randomly assigned (in a 1:1 ratio) to receive either tigecycline or ertapenem via intravenous (IV) administration for up to 28 consecutive days. Subjects receiving ertapenem may also receive vancomycin for MRSA, coagulase-negative staphylococci (CNS), or enterococci coverage at the investigator’s discretion.

Goal:
This is a comparison study of the safety and efficacy of a once-daily dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes

Investigators:

• Lance R. Peterson, MD (Principal Investigator)
• Michael Howard, MD (Co-Investigator)

Sponsors:

• Wyeth Pharmaceuticals

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:33:25 AM